Table 1 Ongoing (recruiting or active) clinical trials for CpG ODNs. Results were generated by searching ClinicalTrials.gov with queries “Cancer” and X, where X was “CpG,” “SD-101,” “IMO-2125,” “MGN1703,” “SMP-001,” “CSI-2,” or “GNKG168.” Trials were filtered for recruiting, active not recruiting, or enrolling by invitation
From: The promise and challenge of cancer microbiome research
NCT number | Sponsors | Study location | Disease | CpG ODN | Combination therapy | Phase |
|---|---|---|---|---|---|---|
NCT03831295 | Ronald Levy Bristol-Myers Squibb | Stanford Cancer Institute Palo Alto, Palo Alto, CA, USA | Malignant solid neoplasm | SD-101 | BMS 986178 (anti-OX40) | 1 |
NCT03410901 | Ronald Levy National Cancer Institute (NCI) | Stanford University, School of Medicine, CA, USA | Lymphoma | SD-101 | BMS 986178, radiation | 1 |
NCT02927964 | Robert Lowsky Janssen, LP National Institutes of Health (NIH) | Stanford University, School of Medicine, CA, USA | Lymphoma | SD-101 | Ibrutinib (BTK inhibitor), radiation | 1, 2 |
NCT03007732 | Lawrence Fong Prostate Cancer Foundation Merck Sharp & Dohme Corp. Dynavax Technologies Corporation | University of California San Francisco, San Francisco, CA, USA | Prostatic neoplasm | SD-101 | Pembrolizumab, androgen deprivation therapy, radiation | 2 |
NCT04050085 | University of California, Davis National Cancer Institute (NCI) Bristol-Myers Squibb Dynavax Technologies Corporation | University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA | Metastatic/refractory pancreatic cancer, stage IV pancreatic cancer | SD-101 | Nivolumab (anti-PD-1), radiation | 1 |
NCT02521870 | Dynavax Technologies Corporation Merck Sharp & Dohme Corp. | 45 study locations | Metastatic melanoma, head neck cancer | SD-101 | Pembrolizumab (anti-PD-1) | 1, 2 |
NCT03322384 | University of California, Davis | University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA | Lymphoma, advanced solid tumors | SD-101 | Epacadostat (IDO1 inhibitor), radiation | 1, 2 |
NCT01042379 | QuantumLeap Healthcare Collaborative | 26 study locations | Breast neoplasms, tumors, cancer, angiosarcoma | SD-101 | Pembrolizumab (anti-PD-1) | 2 |
NCT03438318 | Checkmate Pharmaceuticals Novella Clinical | 5 study locations | Non-small cell lung cancer | CMP-001 | Atezolizumab (anti-PD-L1), radiation | 1 |
NCT03507699 | Sheba Medical Center Checkmate Pharmaceuticals Bristol-Myers Squibb | Sheba Medical Center, Ramat Gan, Israel | Malignant colorectal neoplasms, liver metastases | CMP-001 | Nivolumab, ipilimumab, radiation | 1 |
NCT02554812 | Pfizer | 94 study locations | Advanced cancer | CMP-001 | Avelumab (anti-PD-L1), utomilumab (4-IBB agonist), PF-04518600(OX40 agonist), PD 0360324 (anti-CSF1) | 2 |
NCT03618641 | Diwakar Davar Checkmate Pharmaceuticals University of Pittsburgh | UPMC Hillman Cancer Center, Pittsburgh, PA, USA | Melanoma, lymph node cancer | CMP-001 | Nivolumab | 2 |
NCT03084640 | Checkmate Pharmaceuticals | 4 study locations | Malignant melanoma | CMP-001 | Pembrolizumab | 1 |
NCT02680184 | Checkmate Pharmaceuticals | 13 study locations | Melanoma | CMP-001 | Pembrolizumab | 1 |
NCT03865082 | Idera Pharmaceuticals, Inc. Bristol-Myers Squibb | 3 study locations | Solid tumors | IMO-2125 | Nivolumab (anti-PD1), ipilimumab (anti-CTLA-4) | 2 |
NCT03445533 | Idera Pharmaceuticals, Inc. Bristol-Myers Squibb | 102 study locations | Metastatic melanoma | IMO-2125 | Ipilimumab | 3 |
NCT02644967 | Idera Pharmaceuticals, Inc. | 10 study locations | Metastatic melanoma | IMO-2125 | Ipilimumab, pembrolizumab (anti-PD-1) | 1, 2 |
NCT04126876 | A.J.M. van den Eertwegh Idera Pharmaceuticals, Inc. | VU Medical Center, Amsterdam, the Netherlands | Malignant melanoma | IMO-2125 | 2 | |
NCT02077868 | Mologen AG | 127 study locations | Metastatic CRC | MGN1703 | Usual maintenance | 3 |
NCT02668770 | M.D. Anderson Cancer Center Mologen AG | University of Texas MD Anderson Cancer Center, Houston, TX, USA | Advanced cancers, melanoma | MGN1703 | Ipilimumab | 1 |
NCT02452697 | David Rizzieri, MD Agilent Technologies, Inc. | Duke University Health System, Durham, NC, USA | Myeloid malignancies, lymphoid malignancies | DUK-CPG-001 | NK-enriched donor lymphocyte infusion (DLI) | 2 |